Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

Peer Review reports

Original Submission
9 Apr 2018	Submitted	Original manuscript
8 Jun 2018	Author responded	Author comments - Kazuhiro Araki
Resubmission - Version 2
8 Jun 2018	Submitted	Manuscript version 2
17 Jul 2018	Reviewed	Reviewer Report - Anthony D. Elias
7 Sep 2018	Reviewed	Reviewer Report - Georg Pfeiler
27 Sep 2018	Author responded	Author comments - Kazuhiro Araki
Resubmission - Version 3
27 Sep 2018	Submitted	Manuscript version 3
Publishing
2 Oct 2018	Editorially accepted
16 Oct 2018	Article published	10.1186/s12885-018-4888-2

Back to article page